Synergistic findings from microbiological and evolutional analyses of virulence factors among pathogenic streptococcal species
ConclusionBacterial pathogens rapidly adapt to clinical intervention, such as antimicrobial agents and vaccination, via horizontal gene transfer, recombination, and/or natural point mutation. It is vital to continue development of innovative analysis methods to counter the mounting threats from evolving bacteria.
Ming Tan, Johannes H. Hegemann and Christine Sütterlin present a new book on Chlamydia Biology: From Genome to Disease This book provides an up-to-date review of the clinical infections caused by the two main human pathogens C. trachomatis and C. pneumoniae, as well as chapters on veterinary Chlamydia species and Chlamydia-related bacteria. Multiple chapters cover cutting-edge developments in Chlamydia research, from the basic biology of the intracellular chlamydial infection to the host immune response and work towards a Chlamydia vaccine. Also highlighted are recent advances in chlamydial genetics and genomics, whic...
Publication date: Available online 18 October 2019Source: Journal of Microbiology, Immunology and InfectionAuthor(s): Yu-Chin Huang, Chin-Fu Lin, Pei-Ju Ting, Tzu Han Tang, Fang-Liang Huang, Huei-Jen Chao, Chun-Lung Wang, Po-Yen ChenAbstractBackground/PurposeAntimicrobial resistance in Taiwan has been on the rise for two decades. The implementation of pneumococcal conjugate vaccination (PCV13) and enhanced antimicrobial control (2013-2015) by the government may have changed the antibiotic resistance.MethodsFour respiratory pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, and Moraxella ca...
Conclusions: PCV13 administered as a 3- or 2-dose infant series followed by a toddler dose was immunogenic and well tolerated in healthy Chinese infants and likely protective against PCV13 serotypes; immune responses with a 2-dose schedule were lower for some serotypes.
ConclusionsSOPs may provide a good starting point for increasing adult immunization coverage rates. Using additional interventions, quality-based metrics, or incentives could lead to sustained adult immunization prioritization.
CONCLUSIONS: Our findings demonstrate that nasal colonization with pneumococcus and microaspiration prime AM, leading to brisker responsiveness to both pneumococcus and unrelated bacterial pathogens. The relative abundance of AM in the alveolar spaces, alongside with their potential for non-specific protection, render them an attractive target for novel vaccines. Clinical trial registration available at http://www.isrctn.com, ID: ISRCTN16993271. PMID: 31626559 [PubMed - as supplied by publisher]
Outbreaks of severe pneumococcal disease occur sporadically and can affect large numbers of individuals, although they are less frequent compared to the pre-antibiotic era.1 The responsible pathogen, Streptococcus pneumoniae, is a Gram-positive bacterium that commonly colonises the nasopharyngeal tract, especially in young children. Occasionally, however, it can invade locally to cause mucosal infections including sinusitis, otitis media or pneumonia. Rarely, invasion of the bloodstream can lead to more serious infections, including septicaemia and meningitis.
Authors: Lamichhane PP, Samarasinghe AE Abstract Influenza virus infection is a serious threat to humans and animals, with the potential to cause severe pneumonia and death. Annual vaccination strategies are a mainstay to prevent complications related to influenza. However, protection from the emerging subtypes of influenza A viruses (IAV) even in vaccinated individuals is challenging. Innate immune cells are the first cells to respond to IAV infection in the respiratory tract. Virus replication-induced production of cytokines from airway epithelium recruits innate immune cells to the site of infection. These leuko...
In response to AAFP concerns that some physicians'Medicare claims for administering pneumococcal vaccinations have been denied, CMS has instructed Medicare contractors to cease local pneumococcal vaccination frequency edits.
Publication date: 2019Source: The Journal of the Economics of Ageing, Volume 14Author(s): J.P. Sevilla, Andrew Stawasz, Daria Burnes, Peter Bo Poulsen, Reiko Sato, David E. Bloom
CONCLUSIONS: Indigenous adult vaccination coverage for influenza and pneumococcal disease remains unacceptably low. Between 2004-05 and 2012-13, declines occurred in pneumococcal vaccination coverage across all age groups ≥18 years. Despite national funding of influenza vaccine in 2010, there was no increase in influenza coverage, except for the 18-49-year age group. Implications for public health: Current approaches to promote, deliver and monitor vaccination of Indigenous adults are inadequate. PMID: 31617660 [PubMed - as supplied by publisher]